Anaplasticcarcinoma of the ovary: A single-institution experience and molecular analysis. We describe a tertiary referral center's experience with anaplastic ovarian carcinoma and characterize the genetic landscape of these rare tumors. Anaplastic ovarian carcinomas were retrospectively identified from institutional databases from 2013 to 2023. Clinical data and survival outcomes were
SWI/SNF protein and claudin-4 expression in anaplasticcarcinomas arising in mucinous tumours of the ovary and retroperitoneum. Anaplasticcarcinoma arising in a mucinous tumour of the ovary and rarely in the retroperitoneum is an uncommon neoplasm with three morphological patterns; rhabdoid, sarcomatoid and pleomorphic. We investigated expression of switch/sucrose non-fermentable (SWI/SNF (56%) showed loss of more than one protein, with dual loss of SMARCA4 and SMARCA2 in two, loss of SMARCA2 and ARID1A in two and loss of SMARCB1 and SMARCA2 in one. Retained expression of claudin-4 was seen in 39% of the anaplasticcarcinomas and within the mucinous component of all tumours. Rhabdoid morphology was associated with poor prognosis [stages III or IV disease (six of six, 100% versus four
Anaplasticcarcinoma of the pancreas diagnosed by endoscopic ultrasound-guided fine-needle aspiration: a case report and review of the literature Anaplasticcarcinoma of the pancreas is a rare pancreatic neoplasm with a poor prognosis. It is classified as a variant of ductal adenocarcinoma, but the clinical features and treatment of it remain unknown because of its rarity and aggressiveness revealed a heterogeneous lesion. Endoscopic ultrasound-guided fine-needle aspiration showed pleomorphic atypical cells. We diagnosed anaplasticcarcinoma of the pancreas. We resected the lesion, and she has shown no sign of recurrence for > 6 months. There are few reports of anaplasticcarcinoma of the pancreas diagnosed by endoscopic ultrasound-guided fine-needle aspiration and treated by surgery. Our
Anaplasticcarcinoma in ovarian seromucinous cystic tumor of borderline malignancy The mortality rate of ovarian cancer is the highest among all gynecological malignancies in Japan. Ovarian tumors are classified as benign, borderline malignant, or malignant. Anticipating the histological subtype with imaging only is often difficult because of several histological subtypes of epithelial ovarian have reported a 53-year-old Japanese woman with anaplasticcarcinoma in an ovarian seromucinous cystic tumor of borderline malignancy. Her MRI and CT analysis revealed an ovarian tumor with a mural nodule, ascites, and peritoneal dissemination. Enhanced MRI revealed that the mural nodule was enhanced. Enhanced CT analysis revealed that the lymph nodes were not swollen. Intriguingly, the mural nodule
AnaplasticCarcinoma of the Pancreas: A Rare Clinical Entity Anaplasticcarcinoma of the pancreas (ACP) is a very rare histologic subtype of pancreatic cancer and associated with more aggressive and poor prognosis than pancreatic ductal adenocarcinoma. We aimed to review this rare entity and discuss its clinical features, diagnosis and therapy. We presented a case of a 63-year-old male patient
Anaplasticcarcinoma of the pancreas: Case report and literature review of reported cases in Japan We report a case of a 64-year-old woman with anaplasticcarcinoma of the pancreas (ACP) with cyst formation and review 60 ACP cases reported in Japan. In 20% of cases, laboratory tests revealed severe anemia (hemoglobin level < 10.0 g/dL) and elevated leucocyte counts (> 12000/mm), which were
Mucinous cystadenocarcinoma of the pancreas with anaplasticcarcinoma: A case report and review of the literature Few reports of mucinous cystic neoplasm (MCN) in association with anaplasticcarcinoma exist. The present study reported an unusual case of a 25-year-old female exhibiting large pancreatic MCN with anaplasticcarcinoma. Notably, the patient was a Jehovah's Witness and therefore was mucinous cystadenocarcinoma of the pancreas with anaplasticcarcinoma. Although the patient underwent postoperative adjuvant chemotherapy with gemcitabine and oral fluoropyrimidine (S-1), recurrence with peritoneal dissemination was detected 20 months following surgery and the patient succumbed to the recurrence 32 months following surgery. To the best of our knowledge, this is the first case report
A case of long-term 24-month survival in pancreatic anaplasticcarcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy We herein describe the case of a 70-year-old female patient diagnosed with pancreatic carcinoma. An abdominal enhanced computed tomography scan revealed a poorly enhanced mass (17mm×15mm in size) in the pancreatic head. Magnetic resonance cholangiopancreatography type). After the surgery, we performed S-1 adjuvant chemotherapy 100mg/day for four weeks, repeated similarly every six weeks for a total of four courses. We have followed this case for over 2 years so far with adjuvant chemotherapy, and no recurrence or metastasis has been revealed. Adjuvant chemotherapy with S-1 in patients with resected anaplasticcarcinoma of the pancreas is also recommended
Anaplasticcarcinoma of the pancreas arising in an intraductal papillary mucinous neoplasm: A case report We herein report a case of anaplasticcarcinoma of the pancreas arising in an intraductal papillary mucinous neoplasm (IPMN). A 68-year-old Japanese woman was admitted to our hospital complaining of fatigue. Computed tomography revealed an irregular mass in the pancreatic head, which
Primary Squamous Cell Carcinoma of the Thyroid Diagnosed as AnaplasticCarcinoma: Failure in Fine-Needle Aspiration Cytology? A case of primary squamous-cell carcinoma (SCC) of the thyroid which had been initially diagnosed as an anaplasticcarcinoma (ATC) is described: female, 73 years old, with a fast-growing cervical nodule on the left side and hoarseness for 3 months. Ultrasonography showed
AnaplasticCarcinoma and Toxic Multinodular Goiter: An Unusual Presentation A 70-year-old male was referred with hyperthyroidism and multinodular goiter (MNG). Thyroid ultrasonography showed 2 nodules, one in the isthmus and the other in the left lobe, 51 and 38 mm in diameter, respectively. Neck CT showed a large MNG, thyroid scintigraphy showed increased uptake in the nodule in the left lobe
The role of surgery in the treatment of thyroid anaplasticcarcinoma in the elderly. Anaplastic thyroid carcinoma (ATC) is characterized by local invasiveness, risk of recurrence and very poor prognosis. We retrospectively analysed the multimodality treatment of ATC in 79 patients considering the impact of surgery on survival. Patients were divided in two age groups A and B (cut-off 75 years
Thyroid, AnaplasticCarcinoma (Diagnosis) Anaplastic Thyroid Carcinoma: Practice Essentials, Pathophysiology, Epidemiology For YouNews & PerspectiveDrugs & DiseasesCME & EducationAcademyVideoDecision PointEdition:EnglishMedscapeEnglishDeutschEspañolFrançaisPortuguêsUKNewUnivadisLog In Sign Up It's Free!English EditionMedscape * English * Deutsch * Español * Français * Português
Thyroid, AnaplasticCarcinoma (Follow-up) Anaplastic Thyroid Carcinoma Treatment & Management: Approach Considerations, Medical Care, Surgical Care News & PerspectiveDrugs & DiseasesCME & EducationAcademyVideoDecision PointEdition:EnglishMedscapeEnglishDeutschEspañolFrançaisPortuguêsUKNewUnivadisLog In Sign Up It's Free!English EditionMedscape * English * Deutsch * Español * Français * Português
Thyroid, AnaplasticCarcinoma (Treatment) Anaplastic Thyroid Carcinoma Treatment & Management: Approach Considerations, Medical Care, Surgical Care For YouNews & PerspectiveDrugs & DiseasesCME & EducationAcademyVideoDecision PointEdition:EnglishMedscapeEnglishDeutschEspañolFrançaisPortuguêsUKNewUnivadisLog In Sign Up It's Free!English EditionMedscape * English * Deutsch * Español * Français
Phase II trial of sorafenib in patients with advanced anaplasticcarcinoma of the thyroid. Anaplastic thyroid cancer (ATC) is a rare but highly aggressive malignancy with a median survival of 3-5 months. The BRAF oncogene is mutated to its active form in up to 24% of ATC cases. Sorafenib is a tyrosine kinase inhibitor that acts on the RAF-1 serine/threonine kinase. In preclinical mouse models
be made (e.g. lymphoma versus anaplasticcarcinoma), should be placed in the Thy5 category. 5.5 Malignant: Thy5 These are samples that can be confidently diagnosed as malignant. The tumour type should be clearly stated, if possible, for example: • PTC • medullary thyroid carcinoma • anaplastic thyroid carcinoma • lymphoma • other malignancy, including potentially non-thyroid/metastatic malignancy. PG 060324 19 V4 Final Sometimes it may be possible to be confident of malignancy but not of tumour type. This should then be clearly stated and a differential diagnosis given, e.g. between anaplasticcarcinoma and lymphoma, or anaplasticcarcinoma and metastatic malignancy. A particular problem could be NIFTP; see section 7. [Level of evidence B and GPP – ensures consistency of reporting.] 5.6 Thyroid
anaplasticcarcinoma), should be placed in the Thy5 category. 5.5 Malignant: Thy5 These are samples that can be confidently diagnosed as malignant. The tumour type should be clearly stated, if possible, for example: • papillary thyroid carcinoma • medullary thyroid carcinoma • anaplastic thyroid carcinoma • lymphoma • other malignancy, including potentially non-thyroid/metastatic malignancy. Sometimes it may be possible to be confident of malignancy but not of tumour type. This should then be clearly stated and a differential diagnosis given, e.g. between anaplasticcarcinoma and lymphoma, or anaplasticcarcinoma and metastatic malignancy. A particular problem could be NIFTP; see section 7. [Level of evidence B and GPP – ensures consistency of reporting.] 5.6 Thyroid cytology coding All thyroid